Omeros Corporation (OMER) Company Overview

What does Omeros Corporation do?

Omeros Corporation is a Seattle-based biotechnology company listed on Nasdaq under the ticker OMER. It discovers, develops, and now commercializes protein and small-molecule therapeutics, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The defining change in the company’s profile occurred in December 2025, when the U.S. Food and Drug Administration approved YARTEMLEA, or narsoplimab-wuug, for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The therapy is approved for adults and children age two years and older and became the company’s first internally commercialized medicine.

Which programs define the company today?

The commercial center is YARTEMLEA, a monoclonal antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement. Omeros describes the medicine as the first and only approved treatment for TA-TMA and the first approved lectin-pathway inhibitor. The broader portfolio includes OMS1029, a long-acting MASP-2 antibody that has completed Phase 1 testing; a preclinical small-molecule MASP-2 program; OMS527, a phosphodiesterase-7 inhibitor being studied for cocaine use disorder with National Institute on Drug Abuse funding; OncotoX-AML and other oncology programs; and T-CAT antibodies aimed at multidrug-resistant pathogens. The company’s official research platform therefore spans commercial orphan medicine, complement biology, addiction, oncology, and infectious disease.

How does Omeros make money?

Omeros has shifted from a pre-revenue research company supported by financing and monetized legacy assets into a commercial-stage biotechnology company with several economic engines. The newest and most important is direct U.S. product sales of YARTEMLEA. Omeros sells to wholesalers, records revenue net of chargebacks and distribution fees, and must build transplant-center adoption, formulary access, reimbursement, patient identification, and reliable supply. In the first quarter of 2026, gross product sales were $11.1 million and net product sales were $9.9 million after $1.2 million of provisions for chargebacks and distribution fees.

Why is the Novo Nordisk transaction strategically important?

In November 2025, Omeros closed the sale and license of zaltenibart, formerly OMS906, to Novo Nordisk. The buyer received exclusive global rights to develop and commercialize the MASP-3 antibody and related assets. Omeros reported that potential consideration could reach an aggregate $2.1 billion through upfront and milestone payments, plus tiered royalties on global net sales. The transaction generated a $237.6 million accounting gain in the fourth quarter of 2025, funded debt repayment, and reduced ongoing OMS906 research spending. It also transferred much of the future development cost and execution risk to a larger pharmaceutical partner while preserving contingent upside.

Which revenue stream matters most now?

For near-term operating analysis, YARTEMLEA matters most because it is recurring commercial revenue under Omeros’ direct control. Partner milestones can be larger but episodic. OMIDRIA contributes accounting income and asset value, although much of the U.S. royalty cash is pledged to DRI. The critical investor question is whether YARTEMLEA can grow from launch inventory orders into durable patient-level demand. The company’s first-quarter 2026 results are the first meaningful commercial evidence.

What does Omeros’s latest quarter show?

The quarter ended March 31, 2026 was unusual because reported net income was dominated by a non-cash fair-value gain rather than normal operating profitability. Omeros recorded $9.9 million of net product sales, $0.6 million of product cost, and a $17.4 million operating loss. Yet a $73.1 million non-cash gain from marking the embedded derivative in its 2029 convertible notes to market pushed reported net income to $56.1 million. Management also presented an adjusted net loss of $17.1 million excluding that derivative movement. Researchers should therefore separate launch progress from accounting volatility.

What does the launch gross margin really mean?

Net product sales of $9.893 million less $0.587 million of product cost imply an initial gross profit of about $9.306 million and a reported gross margin near 94.1%. That margin should not be treated as a mature run-rate. Omeros explained that inventory manufactured before regulatory approval had largely been expensed through R&D, leaving low or zero book cost in the launch inventory. As newly manufactured commercial inventory flows through cost of sales, the margin should normalize. The latest Form 10-Q is therefore more informative than the headline margin alone.

Which strategic turning points shaped Omeros?

Omeros’s current business is easier to understand as a sequence of scientific and financing choices rather than as a conventional product-line expansion. The company repeatedly converted internally developed assets into cash or partnership economics, then redirected capital toward complement therapeutics and proprietary discovery platforms.

1. 1994
   Gregory A. Demopulos founded Omeros and became chief executive. Founder continuity still influences scientific priorities, governance, and risk tolerance.
2. 2009
   Omeros completed its initial public offering, giving the research organization access to public equity capital for long-duration drug development.
3. 2014
   FDA approval of OMIDRIA established Omeros’s first commercial validation and later created a monetizable royalty stream.
4. 2021–2024
   The company sold OMIDRIA to Rayner and then monetized portions of future U.S. royalties with DRI, trading future cash flow for immediate liquidity.
5. November 2025
   The zaltenibart transaction with Novo Nordisk produced major proceeds, reduced debt, and transferred a costly late-stage complement program to a global partner.
6. December 2025
   FDA approval of YARTEMLEA changed Omeros from a pipeline company into a commercial rare-disease business with direct product revenue.
7. June–July 2026
   A negative CHMP opinion created a European setback, while note repurchases reduced potential equity-linked debt dilution and reshaped the balance sheet.

What did the OMIDRIA monetization teach investors?

OMIDRIA shows Omeros’s willingness to sell or finance mature economics to fund earlier-stage programs. At March 31, 2026, the OMIDRIA contract royalty asset was $119.2 million, down from $121.8 million at year-end 2025 after royalties earned and remeasurement adjustments. During Q1 2026, discontinued operations contributed $4.8 million of net income. The asset remains economically meaningful, but cash receipts and accounting income differ because royalties are routed under the DRI arrangement. This makes cash-flow analysis more complex than simply adding royalty income to product sales.

What gives Omeros a competitive advantage?

The strongest advantage is scientific specificity rather than scale. YARTEMLEA selectively inhibits MASP-2 in the lectin pathway while preserving classical and alternative complement functions. That mechanistic differentiation matters because infection risk and immune-function trade-offs shape how complement inhibitors are used. The approved label covers TA-TMA patients age two and older, giving Omeros a first-mover position in an orphan condition with no previously approved U.S. therapy.

In complement therapeutics, Omeros faces larger organizations including AstraZeneca’s Alexion, Novartis, Apellis, and Roche, all of which have deeper commercial infrastructure and established hematology relationships. In TA-TMA, the practical competition also includes fragmented diagnosis, supportive care, off-label practices, hospital budget constraints, and emerging clinical programs. Omeros must convert its first-approved position into transplant-center protocols before larger or newer alternatives narrow the lead.

How durable is the YARTEMLEA position?

Durability depends on four linked factors. First, clinicians must identify TA-TMA early and incorporate YARTEMLEA into transplant protocols. Second, reimbursement must support hospital economics. CMS assigned a permanent product-specific J-code effective July 1, 2026, simplifying billing, and had proposed a New Technology Add-On Payment pathway for high-cost inpatient use. Third, Omeros must maintain dependable supply and safety monitoring. Fourth, future competitive products or off-label alternatives could challenge pricing or adoption. The FDA approval announcement supports the first-mover case, but commercial execution determines whether that scientific lead becomes an economic moat.

How financially strong is Omeros?

The balance sheet is stronger than it was before the Novo Nordisk transaction, but the company is not yet self-funding. Cash, cash equivalents, and short-term investments totaled $135.3 million at March 31, 2026. Operating cash use was $14.5 million in Q1 2026, compared with $35.8 million in Q1 2025. Omeros repaid the final $17.1 million of its 2026 notes in February and reported $70.8 million principal of 2029 convertible notes at quarter-end. It also repurchased $4.2 million of common stock during the quarter at an average $11.70 per share.

Why can reported earnings mislead?

The convertible-note embedded derivative can create large mark-to-market gains or losses when Omeros’s share price and interest-rate assumptions change. Q1 2026’s $73.1 million gain converted an operating loss into reported net income. That gain did not produce operating cash. A better operating lens combines net product sales, gross-to-net deductions, normalized product cost, R&D, SG&A, and cash burn. This is especially important because Omeros’s stock-linked financing can make GAAP earnings volatile even when the underlying commercial trajectory changes gradually.

How did capital allocation change in July 2026?

After quarter-end, Omeros agreed to repurchase $16.0 million principal of 2029 notes for approximately $31.3 million, leaving about $54.8 million principal outstanding. It then signed agreements to repurchase up to another $14.5 million principal for up to about $31.0 million, potentially reducing remaining principal to approximately $40.3 million. The July 2026 Form 8-K shows management prioritizing removal of equity-linked debt, but at a substantial cash cost and above principal value.

Who owns Omeros stock and why does governance matter?

Omeros has one class of common stock and no dual-class voting structure, but founder influence is significant. Gregory A. Demopulos, M.D., founded the company in 1994 and serves as president, chief executive officer, and board chair. The 2026 proxy reported 72,168,330 shares outstanding on April 17, 2026. Dr. Demopulos beneficially owned 5,880,350 shares including exercisable options, equal to 7.7%. Directors and executive officers as a group beneficially owned 8,173,564 shares, or 10.5%. BlackRock was the only listed greater-than-5% outside holder, with 4,279,836 shares, or 5.9%.

How independent is the board?

The proxy identified eight directors, of whom six met Nasdaq and SEC independence standards. Gregory Demopulos and his brother, Peter A. Demopulos, were not independent. Thomas J. Cable served as lead independent director. The board was classified into three director classes with staggered terms, which can provide continuity but can also make rapid board change more difficult. Founder leadership offers long-term scientific consistency, yet it also increases key-person and succession risk. The 2026 proxy statement is the primary source for ownership, board composition, and compensation incentives.

Which KPIs matter most for Omeros?

Traditional revenue growth is now relevant, but a biotechnology launch requires a wider dashboard. The most decision-useful metrics connect patient access, commercial quality, cash consumption, and pipeline optionality. No single quarter can establish a stable sales curve because wholesaler inventory, timing of patient starts, gross-to-net estimates, and reimbursement milestones can create noise.

What opportunities could change the Omeros story?

The largest opportunity is successful U.S. commercialization of YARTEMLEA. TA-TMA is severe, often underdiagnosed, and concentrated within a finite network of transplant centers, which can make targeted commercialization efficient. Omeros has cited approximately 30,000 allogeneic transplants annually across the U.S. and Europe and studies estimating TA-TMA in up to 56% of recipients, although the commercially treatable population will be lower and depends on diagnosis, severity, clinical practice, and reimbursement.

Where can pipeline optionality create value?

OMS1029 could extend Omeros’s MASP-2 franchise into additional complement-mediated diseases with less frequent dosing. A selected small-molecule MASP-2 candidate could broaden delivery options. OMS527 is notable because external NIDA funding reduces Omeros’s direct cost while preserving potential value in cocaine use disorder. The oncology and T-CAT programs are earlier and carry high scientific risk, but they provide licensing or development options beyond complement. The strategic challenge is sequencing these programs without allowing a broad pipeline to outrun the cash generated by YARTEMLEA and partner economics.

Can partner economics lower financing risk?

Novo Nordisk milestone and royalty potential could be highly valuable if zaltenibart advances, but milestone timing and probability are outside Omeros’s control. OMIDRIA royalty economics provide another asset-backed source, although much U.S. cash is committed to DRI. The best outcome is a portfolio in which YARTEMLEA funds operations, zaltenibart produces partner milestones, and selected pipeline programs attract grants or collaborations. That would reduce reliance on equity issuance and convertible financing.

What risks could weaken Omeros’s outlook?

The risk profile is concentrated. YARTEMLEA is the only commercial product under Omeros’s control, so launch execution, reimbursement, safety, and manufacturing have disproportionate influence. Serious and life-threatening infections were reported in 36% of the 28 clinical-trial patients cited in the company’s safety information, regardless of causality or relatedness, underscoring the complexity of the severely ill transplant population. Any negative safety signal, supply interruption, payer resistance, or slow protocol adoption could reduce sales.

Why is dilution still relevant after debt reduction?

Omeros had 72.0 million shares outstanding at March 31, 2026, versus a basic weighted-average share count of 71.9 million for Q1 2026 and 58.1 million for Q1 2025. Prior note exchanges and equity awards increased the share base. The 2029 notes can also create dilution or cash obligations depending on conversion and settlement. July repurchases may reduce future dilution, but they use liquidity that could otherwise support commercialization or R&D. Investors should analyze debt reduction and cash runway together rather than treating either in isolation.

The company’s 2025 Form 10-K provides the most complete discussion of regulatory, commercial, financing, intellectual-property, cybersecurity, and development risks.

Why does Omeros matter for valuation?

Omeros is not well described by a single revenue multiple or a simple earnings forecast. A valuation needs at least four separate blocks: the probability-weighted value of YARTEMLEA’s U.S. commercial cash flows; the risk-adjusted value of European approval and other geographic expansion; contingent zaltenibart milestones and royalties from Novo Nordisk; and the net value of OMIDRIA royalty assets, cash, debt, and other obligations. Earlier pipeline programs add option value but require heavy probability discounts and future development spending.

Which DCF assumptions matter most?

The central assumptions are the number of treated patients, net price after discounts, treatment duration or dosing pattern, speed of center adoption, normalized gross margin, commercial operating expense, and required post-approval investment. A launch forecast should distinguish wholesaler purchases from end-patient use. It should also avoid extrapolating the 94.1% launch gross margin because pre-approval manufacturing costs were previously expensed. On the balance-sheet side, the analyst must reflect note repurchases after March 31, 2026, the OMIDRIA royalty asset and obligation, and the possibility of future milestone receipts or financings.

What is the right comparable-company lens?

Comparable analysis should emphasize rare-disease commercial biotechnology companies with one primary product, concentrated prescriber networks, high regulatory sensitivity, and meaningful pipeline optionality. Larger diversified pharmaceutical companies are poor direct comparables because their cost of capital, commercial infrastructure, and product concentration differ. Even within small biotechnology, Omeros’s royalty assets and contingent Novo Nordisk economics make enterprise-value comparisons unusually sensitive to balance-sheet adjustments.

What should students and investors monitor next?

Omeros has crossed the most important scientific-commercial boundary: it now has an FDA-approved, directly sold product. The next stage is about proving repeatable economics. The business must turn a first quarter of wholesaler sales into sustained patient demand while funding a broad pipeline and managing a complex capital structure.